{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:47:16Z","timestamp":1791406036479,"version":"4.3.3"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bulcan.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T08:42:26Z","timestamp":1677573746000},"page":"440-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["L\u00e9iomyosarcomes ut\u00e9rins\u00a0\u2013\u00a0R\u00e9f\u00e9rentiel de prise en charge du GSF-GETO\/NETSARC+ et du groupe TMRG"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-5871","authenticated-orcid":false,"given":"B\u00e9r\u00e9nice","family":"Collineau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Genestie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Guyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Llacer-Moscardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coriolan","family":"Lebreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Toulmonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bonvalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Duffaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.01.009_bib0245","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.05.036","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study","volume":"146","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"S3","key":"10.1016\/j.bulcan.2023.01.009_bib0250","article-title":"Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Leiomyosarcomas","volume":"24","author":"Hensley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0255","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396\u00a0patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"de Pinieux","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0265","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jnci\/80.4.233","article-title":"Clinical aspects of postirradiation sarcomas","volume":"80","author":"Robinson","year":"1988","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.bulcan.2023.01.009_bib0270","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/ijgc-00009577-200511000-00049","article-title":"Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases","volume":"15","author":"Yildirim","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.pgp.0000185407.93308.ce","article-title":"Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report","volume":"25","author":"Botsis","year":"2006","journal-title":"Int J Gynecol Pathol"},{"issue":"8","key":"10.1016\/j.bulcan.2023.01.009_bib0280","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53\u00a0germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bulcan.2023.01.009_bib0285","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1017\/S0266462318000168","article-title":"Preoperative magnetic resonance imaging diagnostic features of uterine leiomyosarcomas: a systematic review","volume":"34","author":"Kaganov","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0290","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1148\/radiol.2020191658","article-title":"Diagnostic algorithm to differentiate benign atypical leiomyomas from malignant uterine sarcomas with diffusion-weighted MRI","volume":"297","author":"Abdel Wahab","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1588","article-title":"Percutaneous uterine needle biopsy with microscopic and array-CGH analyses for preoperative sarcoma diagnosis in patients with suspicious myometrial tumors on MRI: a prospective pilot study (SARCGYN)","author":"Smadja","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0300","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/ijgc-2021-002995","article-title":"BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol","volume":"31","author":"Petousis","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2023.01.009_bib0305","first-page":"1001","article-title":"Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior","volume":"52","author":"Giuntoli","year":"2007","journal-title":"J Reprod Med"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0310","first-page":"1241028","article-title":"Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome","author":"Cui","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0315","first-page":"2017","article-title":"Curr Opinion Oncol 2019, comprehensive and integrated genomic characterization of adult soft tissue sarcomas, TCGA","author":"Williams","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0320","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/gcc.22906","article-title":"Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond","volume":"60","author":"Croce","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2023.01.009_bib0325","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/modpathol.2017.185","article-title":"Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77\u00a0tumors","volume":"31","author":"Croce","year":"2018","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.01.009_bib0330","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1078-0432.CCR-19-2891","article-title":"The nanocind signature is an independent prognosticator of recurrence and death in uterine leiomyosarcomas","volume":"26","author":"Croce","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 2","key":"10.1016\/j.bulcan.2023.01.009_bib0335","article-title":"Uterine sarcomas","volume":"131","author":"Prat","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0340","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208\u00a0patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0345","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.01.009_bib0350","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2014.11.011","article-title":"Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis","volume":"137","author":"Bogani","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.01.009_bib0355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2016.11.002","article-title":"Morcellation worsens survival outcomes in patients with undiagnosed uteriane leiomyosarcomas: a retrospective MITO group study","volume":"144","author":"Raspagliesi","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0360","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396\u00a0patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2023.01.009_bib0365","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0090-8258(03)00478-5","article-title":"Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus","volume":"91","author":"Leitao","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0370","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.2008.19.8366","article-title":"Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and American joint committee on cancer staging systems","volume":"27","author":"Zivanovic","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0375","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0380","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ygyno.2019.07.001","article-title":"Meta-analyse adjuvant therapy in early LMS","volume":"154","author":"Chae","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0385","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2013.08.037","article-title":"Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?","volume":"131","author":"Ricci","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.01.009_bib0390","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ygyno.2019.07.001","article-title":"Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis","volume":"154","author":"Chae","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0395","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mds545","article-title":"A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group","volume":"24","author":"Pautier","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0400","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.27942","article-title":"Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2\u00a0trial (SARC 005)","volume":"119","author":"Hensley","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0405","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00454","article-title":"Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a Phase III NRG Oncology\/Gynecologic Oncology Group Study","author":"Hensley","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0410","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"issue":"6\u20137","key":"10.1016\/j.bulcan.2023.01.009_bib0415","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.canrad.2021.06.008","article-title":"Role of radiotherapy for sarcomas","volume":"25","author":"Ducassou","year":"2021","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0420","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.10.064","article-title":"Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors","volume":"116","author":"O\u2019Cearbhaill","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0425","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2\u00a0trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0430","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2007.02.031","article-title":"Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma","volume":"106","author":"Giuntoli","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0435","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7","article-title":"Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)","volume":"55","author":"Muss","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0440","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"D\u2019Ambrosio","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2023.01.009_bib0445","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1470-2045(22)00380-1","article-title":"Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3\u00a0trial","volume":"23","author":"Pautier","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0450","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ygyno.2012.02.014","article-title":"Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis","volume":"125","author":"Leitao","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0455","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/gyno.2002.6840","article-title":"Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma","volume":"87","author":"Leitao","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0460","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ygyno.2003.11.023","article-title":"Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study","volume":"92","author":"Look","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0465","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0470","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9829","key":"10.1016\/j.bulcan.2023.01.009_bib0475","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3\u00a0trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2023.01.009_bib0480","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2005.03.018","article-title":"Temozolomide in uterine leiomyosarcomas","volume":"98","author":"Anderson","year":"2005","journal-title":"Gynecol Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:04Z","timestamp":1757792224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0007455123000504"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.01.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u00e9iomyosarcomes ut\u00e9rins\u00a0\u2013\u00a0R\u00e9f\u00e9rentiel de prise en charge du GSF-GETO\/NETSARC+ et du groupe TMRG","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}